TrialReader


The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

NCT04753385 — Terminated, 138 participants, LivaNova

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04753385, acronym UNCOVER
StatusTerminated - UNCOVER terminated early based on low enrollment and lack of device data collected making analysis unfeasible.
Study typeObservational
Enrollment138 (Actual)
SponsorLivaNova (Industry)
ConditionsTreatment Resistant Depression
Datesstart 2021-03-23, primary completion 2024-09-06, completion 2024-09-06, first posted 2021-02-15, last updated 2024-12-20
Locations33 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Treatment Resistant Depression

-Summary

The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).

Expand all sections  ·  Collapse all

+Detailed description

A prospective, observational, exploratory study collecting passive and active behavioral, environmental and physiological data, via the use of an Android smartphone application and Study Watch.

This sub-study is only open to sites participating in the RECOVER clinical study.

All subjects participating in the RECOVER clinical trial at active UNCOVER sites will be offered participation in this sub-study.

Subjects who opt-in to the Mood App portion of the sub-study will be followed for a minimum of 12 months and a maximum of 60 months for the Mood App portion of the sub-study.

Subjects who opt-in to the use of the Study Watch portion of the sub-study will be followed for a minimum of 12 months and maximum of 24 months for the Study Watch portion of the sub-study.

+Outcome measures

Primary outcomes

  • Percentage of PHQ-8 tasks [Through study completion; Average 2 years]: Percentage of PHQ-8 tasks completed over the duration of the study
  • Percentage of Voice Diary tasks [Through study completion; Average 2 years]: Percentage of Voice Diary tasks completed over the duration of the study
  • Number of ping sensor recordings [Through study completion; Average 2 years]: Number of ping sensor recordings over the duration of the study
  • Number of hours of watch wear time [Through study completion; Average 2 years]: Number of hours of watch wear time over the duration of the study

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

All Subjects

1. Current consented subject in the RECOVER clinical trial;
2. Adult (i.e. ≥ 18 years of age, unless a resident of any U.S. state where the age of majority is 19, in which case must be ≥ 19 years of age);
3. Able and willing to provide written informed consent for this sub-study;
4. Able and willing to comply with all study procedures;
5. Able to read and speak English.

Phone Application

1. Have a personal Google user account or be willing to create and own a personal Google user account;
2. Owns a personal Android smartphone with a data plan and is the sole user of that smartphone;
3. Agrees to download and maintain the phone application onto personal Android smartphone for the duration of the sub-study;

Study Watch

1\. Willing to comply with Study Watch wearing and recharging requirements

Exclusion Criteria:

All Subjects

1\. Any condition or situation the Principal Investigator determines as inappropriate for study inclusion

Phone Application

No additional exclusion criteria for phone application

Study Watch

1\. Subjects with known severe allergy to nickel or metal jewelry

+Locations (33)

FacilityCityCountryStatus
University of Alabama at BirminghamBirmingham, AlabamaUnited States
ATP Clinical Research, Inc.Costa Mesa, CaliforniaUnited States
Keck Hospital of USCLos Angeles, CaliforniaUnited States
SF-Care, Inc.San Rafael, CaliforniaUnited States
Kind Research GroupBoca Raton, FloridaUnited States
APG Research, LLCOrlando, FloridaUnited States
Nova Psychiatry Inc.Orlando, FloridaUnited States
Advanced Mental Health Care Inc.Royal Palm Beach, FloridaUnited States
Florida Center for TMSSaint Augustine, FloridaUnited States
Stedman Clinical TrialsTampa, FloridaUnited States
Augusta UniversityAugusta, GeorgiaUnited States
AMR-Baber Research, Inc.Naperville, IllinoisUnited States
Psychiatric Medicine Associates, LLCSkokie, IllinoisUnited States
Southern Illinois University School of MedicineSpringfield, IllinoisUnited States
Beacon Medical Group Behavioral HealthSouth Bend, IndianaUnited States
Sheppard Pratt Health SystemsBaltimore, MarylandUnited States
Michigan Clinical Research Institute PCAnn Arbor, MichiganUnited States
Psychiatric Care and ResearchO'Fallon, MissouriUnited States
PsychCare Consultants ResearchSt Louis, MissouriUnited States
Alivation Research, LLCLincoln, NebraskaUnited States
Hapworth Research Inc.New York, New YorkUnited States
Center for Neuropsychiatry and Brain Stimulation (CNBS)Cary, North CarolinaUnited States
Ohio State UniversityColumbus, OhioUnited States
OU-SOCM Dept of PsychiatryTulsa, OklahomaUnited States
Scranton Medical InstitutesMoosic, PennsylvaniaUnited States
University of Pennsylvania Perelman School of MedicinePhiladelphia, PennsylvaniaUnited States
UT Health AustinAustin, TexasUnited States
UT Center of Excellence on Mood DisordersHouston, TexasUnited States
North Pointe PsychiatryLewisville, TexasUnited States
Neuropsychiatric Associates, PlcWoodstock, VermontUnited States
Carilion ClinicRoanoke, VirginiaUnited States
Seattle Neuropsychiatric Treatment CenterBellevue, WashingtonUnited States
Center for Anxiety and DepressionMercer Island, WashingtonUnited States

+Investigators

My Notes